What is your preferred chemotherapy regimen for patients with peripheral neuropathy and high risk HR+/HER2- breast cancer?
Community PollStarted
What is your preferred chemotherapy regimen for patients with peripheral neuropathy and high risk HR+/HER2- breast cancer?
74 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet Member
Medical Oncology · University of Iowa Holden Comprehensive Cancer Center
Answered on
Taxanes tend to improve outcome for all subtypes of breast cancer; several trials including BCIRG 001, CALGB-9344, and NSABP B-27 and B-28 have shown taxanes to be an important component of adjuvant chemotherapy regimens for patients with high risk cancers, including Hormone receptor positive, node-...
Join for free or sign in to see the full answer